Baseline characteristics of the patients participating in the ANRS 104 Study. Patients from group 1 started with amprenavir/ritonavir for the first 2 weeks and patients from group 2 started with lopinavir/r
 |
| |||
Baseline characteristics of the patients participating in the ANRS 104 Study. Patients from group 1 started with amprenavir/ritonavir for the first 2 weeks and patients from group 2 started with lopinavir/r
| Parameters | Group 1, amprenavir n=14 | Group 2, lopinavir n=23 |
|---|---|---|
| Median age, years (range) | 47 (32–53) | 41 (27–65) |
| Males, n (%) | 12 (86) | 21 (91) |
|
| ||
| CDC clinical stage, | n (%) | n (%) |
| A | 6 (42) | 10 (43) |
| B | 4 (29) | 3 (13) |
| C | 4 (29) | 10 (43) |
|
| ||
| Median CD4+ cells/mm3 (range) | 195 (65–385) | 185 (3–509) |
|
| ||
| Median HIV1-RNA, log10 copies/mL (range) | 4.9 (3.6–5.7) | 4.6 (3.8–5.6) |
| Median number of previous antiretrovirals (range) | 7.5 (4–12) | 7.5 (4–12) |
| Median number of antiretrovirals taken prior to inclusion and still in use at inclusion (range) | 9.5 (7–13) | 10 (8–13) |
|
| ||
| Genotypic resistance | n (%) | n (%) |
| Amprenavir/r | 7 (50) | 9 (56) |
| Lopinavir/r | 7 (50) | 7 (30) |
|
| ||
| Median (range) number of protease mutations | 7.0 (1.0–9.0) | 7.0 (1.0–10.0) |
|
| ||
| Median (range) number of reverse transcriptase mutations | 6.5 (0–11.0) | 7.0 (0.0–11.0) |
|
| ||
| Median (range) phenotypic resistance index | ||
| Amprenavir | 2.8 (0.5–24.3) | 2.5 (0.5–19.5) |
| Lopinavir | 8.7 (0.3–84.0) | 10.7 (0.2–95.3) |